Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DJ6ZB0
|
|||
| Drug Name |
BGB-16673
|
|||
| Drug Type |
PROTAC
|
|||
| Indication | B-cell lymphoma [ICD-11: 2A86; ICD-10: C85.1; ICD-9: 202.8] | Phase 1 | [1] | |
| Company |
BeiGene
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05294731) A Phase 1, Open-Label, Dose-Escalation and Expansion Study of the Bruton Tyrosine Kinase Targeted Protein-Degrader BGB-16673 in Chinese Patients With B-Cell Malignancies. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.